The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
NACLC 2022 | The emerging role of localized therapy in metastatic NSCLC
Puneeth Iyengar, MD, PhD, UT Southwestern Medical Center, Dallas, TX, comments on current treatment options for patients with metastatic non-small cell lung cancer (NSCLC). Whilst treatment predominantly consisted of systemic therapies such as chemotherapy, there as been a renewed focus on localized therapies. Existing localized treatment mainly consisted of palliative radiotherapy and novel, localized therapies will aim to improve survival in this group of patients. This interview took place at the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Puneeth Iyengar, MD, PhD, has received honoraria from Astrazeneca and Incyte.
